$10bn into new kinase inhibitors, so are there deals around the corner?
This article was originally published in Scrip
Executive Summary
A recent study from the investment firm, MP Advisors, suggests that there could soon be more licensing or M&A deals in the kinase inhibitor area. The extent of deals on phosphoinositide-3-kinase (PI3K), Bruton's tyrosine kinase (BTK) and other kinase inhibitors, has been relatively limited, even though the segment has seen investment of around $10 billion in the past few years.